SCHEMBL2073672

SCHEMBL2073672

Nc1ncnc2c1c(-c1ccc(NC(=O)OCc3ccccc3)c(C(F)(F)F)c1)cn2C1CCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 6/20 0.58
SRC P12931 9/20 0.52
EGFR P00533 8/20 0.52
ABL1 P00519 7/20 0.52
ABL2 P42684 7/20 0.52
LCK P06239 5/20 0.52
KDR P35968 5/20 0.52
FLT3 P36888 4/20 0.52
LYN P07948 3/20 0.52
INSR P06213 2/20 0.52
CSF1R P07333 2/20 0.52
FGFR1 P11362 2/20 0.52
BLK P51451 2/20 0.52
JAK2 O60674 1/20 0.52
NTRK1 P04629 1/20 0.52
NPM1 P06748 1/20 0.52
RET P07949 1/20 0.52
MET P08581 1/20 0.52
ROS1 P08922 1/20 0.52
PDGFRB P09619 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2074654 0.90 IGF1R (0.60) IGF1RSRCEGFRABL1ABL2
SCHEMBL2074582 0.89 IGF1R (0.60) IGF1RSRCEGFRABL1ABL2
SCHEMBL2074490 0.88 SRC (0.61) IGF1RSRCEGFRABL1ABL2
SCHEMBL2072511 0.87 IGF1R (0.59) IGF1RSRCEGFRABL1ABL2
SCHEMBL2074849 0.87 IGF1R (0.58) IGF1RSRCEGFRABL1ABL2
SCHEMBL2071754 0.86 IGF1R (0.59) IGF1RSRCEGFRABL1ABL2
SCHEMBL6885605 0.85 SRC (0.58) IGF1RSRCEGFRABL1ABL2
SCHEMBL2075710 0.85 SRC (0.63) IGF1RSRCEGFRABL1ABL2
SCHEMBL6224136 0.84 IGF1R (0.59) IGF1RSRCEGFRABL1ABL2
SCHEMBL6465185 0.82 IGF1R (0.52) IGF1RSRCEGFRABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 US disclosed
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 US disclosed
WO-2004100868-A2 METHOD OF TREATING TRANSPLANT REJECTION ABBOTT LABORATORIES (US) 2004-11-25 WO disclosed
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN IGF1R 4007/4885SRC 46/4885EGFR 818/4885
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS LCK, PPP5C, DUSP1 IGF1R 439/4885SRC 89/4885EGFR 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.